

08 052051

(3-methyl-TTNCB)  
STANDARDIZED AGONIST DOSE RESPONSE




Fig. 1

RECEPTOR	
—●—	pRShRAR-alpha (wt)
—+—	pRShRAR-beta (wt)
—*—	pRShRAR-gamma (wt)
—○—	pRShRXR-alpha (wt)
—x—	pRSmRXR-beta (wt)
—□—	pRSmRXR-gamma (wt)

(ALL TRANS RETINOIC ACID)  
STANDARDIZED AGONIST DOSE RESPONSE




Fig. 2

RECEPTOR	
—	pRSbRAR-alpha (wt)
—	pRSbRAR-beta (wt)
—	pRSbRAR-gamma (wt)
—	pRSbRXR-alpha (wt)
—	pRSbRXR-beta (wt)
—	pRSbRXR-gamma (wt)

(9CIS RETINOIC ACID)  
STANDARDIZED AGONIST DOSE RESPONSE





Fig. 3



(3-methyl-TTNEB)  
STANDARDIZED AGONIST DOSE RESPONSE





Fig. 4



08 052051

(3-bromo-TTNEB)  
STANDARDIZED AGONIST DOSE RESPONSE





Fig. 5



08.052051

(3-methyl-TTNCHBP)  
STANDARDIZED AGONIST DOSE RESPONSE





Fig. 6



(3-methyl-TTNEHBP)  
STANDARDIZED AGONIST DOSE RESPONSE





Fig. 7



08 052051




Fig. 8



08 052051




Fig. 9

EFFECT OF RETINOIDS ON RAT HDL CHOLESTEROL




Figure 10

08 052051

Myeloma RPMI-8226 Cell Proliferation




Figure 11

Myeloma RPMI-8226 Cell Proliferation




Figure 12